Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Locus Biosciences

Main focus: New treatments against bacterial infections

Company stage: Clinical

Diseases: Urinary tract infection, other infections

Genome editing tool: CRISPR-Cas3

Funding stage: Private

Location: North Carolina, USA


Partners: Janssen Pharma

Locus Biosciences is a clinical-stage gene-editing company focused on treating bacterial infectious diseases. The company uses its next generation sequencing-based platform to rapidly identify new bacterial targets and phages. Locus uses CRISPR-Cas3 crPhages as the base of their therapies. The phages are designed using machine learning in order to optimise effectiveness against new bacterial targets.


HashtagLOCUS Biosciences, Inc.

Company: Locus Biosciences
Search CRISPR Medicine